中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 1
Jan.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(1): 151-159

Risk factors for 90-day mortality in patients with acute-on-chronic liver failure and establishment of a predictive model

DOI: 10.12449/JCH260118
  • 1.

    The First Clinical Medical College of Inner Mongolia Medical University，Hohhot 010059，China

  • 2.

    Department of Gastroenterology，The Affiliated Hospital of Mongolia Medical College，Hohhot 010050，China

  • 3.

    Department of Critical Care Medicine，Hohhot Second Hospital，Hohhot 010050，China

Research funding:

Natural Science Foundation of Inner Mongolia Autonomous Region (2025ZD009);

Natural Science Foundation of Inner Mongolia Autonomous Region (2023QN08061);

Youth Foundation of Inner Mongolia Medical University (YKD2023QN014);

High-level Talent Training Program of the “Grassland Elite” Project （2022） 

More Information
  • Corresponding author: LI Yanmei， 1218520884@qq.com （ORCID： 0009-0005-4677-4057）
  • Received Date: 2025-08-18
  • Accepted Date: 2025-10-14
  • Published Date: 2026-01-25
    Abstract
  •   Objective  To investigate the independent predictive factors for 90-day mortality in patients with acute-on-chronic liver failure （ACLF）， to establish a risk predictive model， and to assess its predictive efficacy in comparison with MELD， MELD-Na， MELD 3.0， and COSSH-ACLF Ⅱ.  Methods  A retrospective analysis was performed for the clinical data of 394 patients with ACLF who were admitted to The Affiliated Hospital of Inner Mongolia Medical University and Hohhot Second Hospital from July 2018 to July 2024， and general information and laboratory markers on admission were collected from all patients. The independent-samples t test or the Mann-Whitney U test was used for comparison of quantitative data between two groups， and the chi-square test or the adjusted chi-square test was used for comparison of qualitative data between two groups. The LASSO regression analysis was used to identify related variables， and the multivariate logistic regression analysis was used to establish a predictive model and generate a nomogram. The receiver operating characteristic （ROC） curve， the area under the ROC curve （AUC）， calibration curve， and clinical decision curve were used to assess the performance of the model.  Results  A total of 394 patients with ACLF were included in this study， with 136 patients in the training set， 58 in the internal validation set， and 200 in the external validation set. The cohort had a mean age of 52.9±11.7 years， among whom male patients accounted for 72.84% （287/394）， the patients with HBV infection accounted for 22.33% （88/394）， the patients with alcohol-related causes accounted for 45.94% （181/394）， and the patients with other causes （including drug-induced and autoimmune diseases） accounted for 31.73% （125/394）. The overall 90-day mortality rate was 27.41% （108/394）. The multivariate logistic regression analysis showed that diabetes （odds ratio ［OR］= 5.831， 95% confidence interval ［CI］： 1.587 — 21.424， P=0.008）， cystatin C （Cys-C） （OR=2.984， 95%CI： 1.501 — 5.933， P=0.002）， and spontaneous peritonitis （SBP） （OR=5.692， 95%CI： 2.150 — 15.071， P<0.001） were independent risk factors， and a nomogram was generated based on these factors. This model had an AUC of 0.836 in the training set， 0.881 in the internal validation set， and 0.878 in the external validation set， showing a good discriminatory ability. The calibration curve showed a good degree of fitting， with a relatively high net clinical benefit. The subgroup analysis based on etiology showed that the model had an AUC of 0.850 in the patients with HBV infection， 0.858 in the patients with alcohol-induced ACLF， and 0.908 in the patients with other etiologies， indicating that the model had a good discriminatory ability across the populations with different etiologies. Compared with traditional scores， the model （AUC=0.836） had a significantly better predictive value than MELD （AUC=0.619， Z=3.197， P=0.001）， MELD-Na （AUC=0.651， Z=2.998， P=0.003）， MELD 3.0 （AUC=0.601， Z=3.682， P<0.001）， and COSSH-ACLF Ⅱ （AUC=0.719， Z=2.396， P=0.017） alone.  Conclusion  Diabetes， SBP， and Cys-C are independent risk factors for 90-day mortality in patients with ACLF. Compared with MELD， MELD-Na， MELD 3.0， and COSSH-ACLF Ⅱ scores， this model has a higher predictive value for 90-day prognosis in patients with ACLF and is suitable for patients with ACLF caused by various etiologies.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association; Nutrition and Regeneration in End-Stage Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the diagnosis and treatment of acute-on-chronic liver failure(2025 version)[J]. J Prac Hepatol, 2025, 28( 5): 641- 647. DOI: 1 0.3969/j.issn.1672-5069.2025.05.001.

    中华医学会肝病学分会重型肝病与人工肝学组, 中华医学会肝病学分会终末期肝病营养与再生学组. 慢加急性肝衰竭诊治指南(2025年版)[J]. 实用肝脏病杂志, 2025, 28( 5): 641- 647. DOI: 10.3969/j.issn.1672-5069.2025.05.001.
    [2]
    MEZZANO G, JUANOLA A, CARDENAS A, et al. Global burden of disease: Acute-on-chronic liver failure, a systematic review and meta-analysis[J]. Gut, 2022, 71( 1): 148- 155. DOI: 10.1136/gutjnl-2020-322161.
    [3]
    LUO JJ, LI JQ, LI P, et al. Acute-on-chronic liver failure: Far to go-a review[J]. Crit Care, 2023, 27( 1): 259. DOI: 10.1186/s13054-023-04540-4.
    [4]
    MOORE O, MA WS, READ S, et al. The unwell patient with advanced chronic liver disease: When to use each score?[J]. BMC Med, 2025, 23( 1): 413. DOI: 10.1186/s12916-025-04185-w.
    [5]
    GÜLCICEGI DE, GOESER T, KASPER P. Prognostic assessment of liver cirrhosis and its complications: Current concepts and future perspectives[J]. Front Med, 2023, 10: 1268102. DOI: 10.3389/fmed.2023.1268102.
    [6]
    LAI RM, CHEN TB, HU YH, et al. Effect of type 2 diabetic mellitus in the prognosis of acute-on-chronic liver failure patients in China[J]. World J Gastroenterol, 2021, 27( 23): 3372- 3385. DOI: 10.3748/wjg.v27.i23.3372.
    [7]
    LUO WL, ZENG Y, ZHANG XM, et al. Influence of metabolism-related factors on the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure and establishment of a predictive model[J]. J Clin Hepatol, 2024, 40( 10): 1985- 1991. DOI: 10.12449/JCH241010.

    罗文苓, 曾玉, 张雪媚, 等. 代谢相关因素对HBV相关慢加急性肝衰竭患者短期预后的影响及预测模型构建[J]. 临床肝胆病杂志, 2024, 40( 10): 1985- 1991. DOI: 10.12449/JCH241010.
    [8]
    FU YF, WU KN, YANG SC, et al. Exploring the predictive value of serum lipids for short-term prognosis in patients with acute-on-chronic liver failure[J]. Portal Hypertens Cirrhosis, 2024, 3( 4): 184- 195. DOI: 10.1002/poh2.93.
    [9]
    CHEN L, DAI JJ, XIE Q, et al. Metabolic risk factors are associated with the disease severity and prognosis of hepatitis B virus-related acute on chronic liver failure[J]. Gut Liver, 2022, 16( 3): 456- 464. DOI: 10.5009/gnl210449.
    [10]
    SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver(APASL): An update[J]. Hepatol Int, 2019, 13( 4): 353- 390. DOI: 10.1007/s12072-019-09946-3.
    [11]
    PIANO S, MAHMUD N, CARACENI P, et al. Mechanisms and treatment approaches for ACLF[J]. Liver Int, 2025, 45( 3): e15733. DOI: 10.1111/liv.15733.
    [12]
    LAI M, XU MM, WANG X, et al. Prognostic evaluation of liver transplantation for acute-on-chronic liver failure[J]. Organ Transplant, 2025, 16( 3): 482- 488.

    赖曼, 徐曼曼, 王鑫, 等. 慢加急性肝衰竭肝移植预后评估[J]. 器官移植, 2025, 16( 3): 482- 488.
    [13]
    DUSEJA A, DE A, TANEJA S, et al. Impact of metabolic risk factors on the severity and outcome of patients with alcohol-associated acute-on-chronic liver failure[J]. Liver Int, 2021, 41( 1): 150- 157. DOI: 10.1111/liv.14671.
    [14]
    LIU C, SHEN J, LI J, et al. DiabetesLiver score: A non-invasive algorithm for advanced liver fibrosis and liver-related outcomes in type 2 diabetes mellitus population[J]. Med, 2025, 6( 8): 100700. DOI: 10.1016/j.medj.2025.100700.
    [15]
    KUMAR A, ARORA A, CHOUDHURY A, et al. Impact of diabetes, drug-induced liver injury, and sepsis on outcomes in metabolic dysfunction associated fatty liver disease-related acute-on-chronic liver failure[J]. Am J Gastroenterol, 2025, 120( 4): 816- 826. DOI: 10.14309/ajg.000000-0000002951.
    [16]
    YE SY, QIN Y. Research progress on the mechanism of diabetes-induced liver injury[J]. Chin Hepatol, 2023, 28( 6): 737- 739. DOI: 10.14000/j.cnki.issn.1008-1704.2023.06.022.

    叶圣莹, 秦燕. 糖尿病致肝损伤机制的研究进展[J]. 肝脏, 2023, 28( 6): 737- 739. DOI: 10.14000/j.cnki.issn.1008-1704.2023.06.022.
    [17]
    ZHANG J, FAN JG. Expert consensus on the management of diabetes mellitus in patients with liver cirrhosis[J]. J Pract Hepatol, 2022, 25( 5): 761- 775.

    张晶, 范建高. 肝硬化合并糖尿病患者血糖管理专家共识[J]. 实用肝脏病杂志, 2022, 25( 5): 761- 775.
    [18]
    XU Z, ZHANG X, CHEN J, et al. Bacterial infections in acute-on-chronic liver failure: epidemiology, diagnosis, pathogenesis, and management[J]. J Clin Transl Hepatol, 2024, 12( 7): 667- 676. DOI: 10.14218/JCTH.2024.00137.
    [19]
    HASSAN A, BHATTI R, HAFEEZ A, et al. Prediction of in-hospital mortality in spontaneous bacterial peritonitis patients with advanced liver disease[J]. Pak J Med Health Sci, 2023, 17( 4): 519- 522. DOI: 10.53350/pjmhs2023174519.
    [20]
    LI SM, LIU J, WU J, et al. Immunological mechanisms and effects of bacterial infections in acute-on-chronic liver failure[J]. Cells, 2025, 14( 10): 718. DOI: 10.3390/cells14100718.
    [21]
    PHILIPS CA, AUGUSTINE P. Gut barrier and microbiota in cirrhosis[J]. J Clin Exp Hepatol, 2022, 12( 2): 625- 638. DOI: 10.1016/j.jceh.2021.08.027.
    [22]
    de OLIVEIRA COBERLLINI JACQUES R, SILVA MASSIGNAN L DA, WINKLER MS, et al. Acute-on-chronic liver failure is independently associated with lower survival in patients with spontaneous bacterial peritonitis[J]. Arq Gastroenterol, 2021, 58( 3): 344- 352. DOI: 10.1590/s0004-2803.202100000-58.
    [23]
    MAIWALL R, SINGH SP, ANGELI P, et al. APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure[J]. Hepatol Int, 2024, 18( 3): 833- 869. DOI: 10.1007/s12072-024-10650-0.
    [24]
    SAHA R, SHARMA S, MONDAL A, et al. Evaluation of acute kidney injury(AKI) biomarkers FABP1, NGAL, cystatin C and IL-18 in an Indian cohort of hospitalized acute-on-chronic liver failure(ACLF) patients[J]. J Clin Exp Hepatol, 2025, 15( 3): 102491. DOI: 10.1016/j.jceh.2024.102491.
    [25]
    IQBAL R, GADDAM M, MOUSTAFA A, et al. The clinical utility of cystatin C in detecting renal dysfunction in cirrhosis: overcoming the limitations of serum creatinine[J]. AAnn Med Surg, 2024. DOI: 10.1097/MS9.0000-000000002822.
    [26]
    AUMPAN N, LIMPRUKKASEM T, PORNTHISARN B, et al. Plasma cystatin C level is a prognostic marker of morbidity and mortality in hospitalized decompensated cirrhotic patients[J]. J Med Invest, 2021, 68( 3.4): 302- 308. DOI: 10.2152/jmi.68.302.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(7)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (74) PDF downloads(34) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return